ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
E555162
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
All labels observed (1)
How this entity was disambiguated
This entity first appeared as the object of triple T5932679 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Context triple: [ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, relatedTo, ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals]
-
A.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
ICH E6 Good Clinical Practice
ICH E6 Good Clinical Practice is an international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials involving human subjects.
-
D.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
E.
Conditional Marketing Authorization by European Medicines Agency
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Target entity description: ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
-
A.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
-
B.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
C.
ICH E6 Good Clinical Practice
ICH E6 Good Clinical Practice is an international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials involving human subjects.
-
D.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
E.
Conditional Marketing Authorization by European Medicines Agency
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
ICH guideline
ⓘ
regulatory guideline ⓘ |
| addresses |
bridging strategies between regions
ⓘ
flexibility based on clinical context and risk ⓘ risk mitigation for human subjects in clinical trials ⓘ |
| aimsTo |
avoid redundant nonclinical testing across regions
ⓘ
ensure adequate safety margins for human exposure ⓘ support ethical use of animals in research ⓘ |
| appliesTo |
biotechnological products
ⓘ
pharmaceuticals for human use ⓘ small-molecule drugs ⓘ |
| covers |
carcinogenicity study considerations
ⓘ
duration of repeated-dose toxicity studies ⓘ genotoxicity testing requirements ⓘ reproductive and developmental toxicity testing strategy ⓘ safety pharmacology requirements ⓘ special toxicity studies when warranted ⓘ timing of nonclinical studies relative to clinical trials ⓘ toxicology study design recommendations ⓘ |
| defines |
nonclinical data needed to support clinical trial progression
ⓘ
nonclinical data needed to support first-in-human clinical trials ⓘ nonclinical data needed to support marketing authorization ⓘ |
| endorsedBy |
European Medicines Agency
NERFINISHED
ⓘ
Pharmaceuticals and Medical Devices Agency Japan NERFINISHED ⓘ U.S. Food and Drug Administration NERFINISHED ⓘ |
| issuedBy | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use NERFINISHED ⓘ |
| objective |
facilitate timely conduct of clinical trials
ⓘ
harmonize global requirements for nonclinical safety studies ⓘ reduce unnecessary animal use in drug development ⓘ support global drug development programs ⓘ |
| partOf | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines NERFINISHED ⓘ |
| provides |
decision trees for nonclinical program design
ⓘ
guidance on duration of chronic toxicity studies for marketing applications ⓘ guidance on timing of reproductive toxicity studies ⓘ recommendations for exploratory clinical trials ⓘ |
| region |
European Union
NERFINISHED
ⓘ
Japan NERFINISHED ⓘ United States of America ⓘ
surface form:
United States
|
| relatedTo |
ICH S1 Carcinogenicity Studies Guidelines
NERFINISHED
ⓘ
ICH S5 Reproductive Toxicity Testing Guidelines NERFINISHED ⓘ ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals NERFINISHED ⓘ ICH S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization NERFINISHED ⓘ |
| replaces | ICH M3(R1) NERFINISHED ⓘ |
| scope |
nonclinical safety studies to support all phases of clinical development
ⓘ
nonclinical safety studies to support marketing authorization applications ⓘ |
| shortName | ICH M3(R2) NERFINISHED ⓘ |
| subjectOf | nonclinical safety studies requirements ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Description of subject: ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
→
relatedTo
→
ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ⓘ